Caribou Biosciences

Caribou Biosciences

Caribou Biosciences is a Berkeley California based private company founded in 2011 by Jennifer Doudna and Rachel Haurwitz based on CRISPR technology.

All edits

Edits on 29 April, 2020
Nico Faraguna
Nico Faraguna edited on 29 April, 2020 10:02 pm
Edits made to:
Infobox (--1 properties)

Infobox

B2X
Edits on 9 February, 2020
Henry Ogolla
Henry Ogolla approved a suggestion from Golden's AI on 9 February, 2020 3:42 pm
Edits made to:
Article (+20/-20 characters)

Article

On April 2, 2015 Caribou Biosciences completed their series A funding round with $11 million in funding from Fidelity BiosciencesFidelity Biosciences, Novartis, Mission Bay Capital, 5 Prime Ventures, and an undisclosed strategic partner.

Aime Anne Nisay
Aime Anne Nisay approved a suggestion from Golden's AI on 9 February, 2020 12:22 pm
Edits made to:
Article (+14/-14 characters)

Article

On May 16, 2016 Caribou Biosciences completed their series B funding round with $30 million in funding from Anterra Capital, Heritage GroupHeritage Group, Maverick Capital Ventures, Pontifax AgTech, F-Prime Capital Partners, Novartis, Mission Bay Capital, and 5 Prime Ventures.

Edits on 30 January, 2020
Henry Ogolla
Henry Ogolla approved a suggestion from Golden's AI on 30 January, 2020 6:26 am
Edits made to:
Article (+15/-15 characters)

Article

On May 16, 2016 Caribou Biosciences completed their series B funding round with $30 million in funding from Anterra Capital, Heritage Group, Maverick Capital Ventures, Pontifax AgTechPontifax AgTech, F-Prime Capital Partners, Novartis, Mission Bay Capital, and 5 Prime Ventures.

Golden AI
Golden AI edited on 30 January, 2020 2:25 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 6 December, 2019
Golden AI
Golden AI edited on 6 December, 2019 9:28 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 26 November, 2019
Golden AI
Golden AI edited on 26 November, 2019 3:58 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 30 May, 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 30 May, 2019 9:13 pm
Edits made to:
Article (+9/-9 characters)

Article

Caribou Biosciences co-founded Intellia Therapeutics to use the Caribou CRISPR-Cas9 platform to develop therapeutics. Intellia Therapeutics is working with RegeneronRegeneron to develop a gene knockout strategy for Transthyretin Amyloidosis (ATTR). CRISPR-Cas9 technology to knock out Hepatitis B Virus is being tested in animal models. Intellia is also developing the technology for gene editing in Alpha-1 Antitrypsin Deficiency (AATD) and Primary Hyperoxaluria (PH-1). Novartis is collaborating with Intellia to edit hemopoietic stem cells ex vivo at the BCL11A gene to treat Sickle Cell Disease. The two companies are also collaborating on Chimeric Antigen Receptor T Cell (CAR-T) strategies which modify the immune system so it better targets cancer.

Edits on 30 May, 2019
Will Suter
Will Suter approved a suggestion from Golden's AI on 30 May, 2019 2:11 am
Edits made to:
Article (+12/-12 characters)

Article

Caribou Biosciences is headquartered in Berkeley, California and was founded in 2011 by to James Berger, Jennifer A. Doudna, Martin JinekMartin Jinek, and Rachel E. Haurwitz. The company uses CRISPR (Clustered Regularly Interspaced Palindromic Repeats) technology, based on a bacterial defense system against viruses, as a biotechnology tool. Co-founder and CEO Racheal Haurwitz was formerly a PhD student mentored by co-founder Jennifer Doudna at UC Berkeley, one of the inventors that turned this bacterial defense system into a customizable gene editing system.

Jed Christiansen
Jed Christiansen approved a suggestion from Golden's AI on 29 May, 2019 9:54 pm
Edits made to:
Article (+15/-15 characters)

Article

On May 16, 2016 Caribou Biosciences completed their series B funding round with $30 million in funding from Anterra CapitalAnterra Capital, Heritage Group, Maverick Capital Ventures, Pontifax AgTech, F-Prime Capital Partners, Novartis, Mission Bay Capital, and 5 Prime Ventures.

Golden AI
Golden AI edited on 29 May, 2019 9:50 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 29 May, 2019
Golden AI
Golden AI edited on 29 May, 2019 7:49 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 11 April, 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 11 April, 2019 7:04 pm
Edits made to:
Article (+6/-6 characters)

Article

There is a patent dispute between Doudna’s research team and the Broad Institute (MIT and Harvard) over the invention of CRISPR-Cas9 technology for use in human cells. The US patent granted to the Broad Institute is under appeal. The European patent office has revoked this first patent obtained by the Broad Institute citing lack of novelty. The European patent office has granted patents to the University of California and University of ViennaVienna. One for using the CRISPR-Cas9 system across prokaryotic and eukaryotic systems and another for a modified form of CRISPR-Cas9 to regulate gene expression. Numerous patents have been assigned to Caribou Biosciences for CRISPR-Cas9 adaptations and other molecular biology materials.

Edits on 9 April, 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 9 April, 2019 6:38 pm
Edits made to:
Article (+19/-19 characters)

Article

On May 16, 2016 Caribou Biosciences completed their series B funding round with $30 million in funding from Anterra Capital, Heritage Group, Maverick Capital Ventures, Pontifax AgTech, F-Prime Capital Partners, Novartis, Mission Bay CapitalMission Bay Capital, and 5 Prime Ventures.

Edits on 4 April, 2019
Dawson Sewell
Dawson Sewell edited on 4 April, 2019 8:56 pm
Edits made to:
Infobox (+5 properties)
Article (+662/-187 characters)
Documentaries, videos and podcasts (+4 rows) (+12 cells) (+401 characters)
Categories (+1/-2 topics)
Related Topics (+2 topics)

Article

Caribou Biosciences is headquartered in Berkeley, California and was formedfounded in 2011 by to useJames Berger, Jennifer A. Doudna, Martin Jinek, and Rachel E. Haurwitz. The company uses CRISPR (Clustered Regularly Interspaced Palindromic Repeats) technology, based on a bacterial defense system against viruses, as a biotechnology biotechnology tool. Co-founder and CEO Racheal Haurwitz was formerly a PhD student mentored by co-founder Jennifer Doudna at UC Berkeley, one of the inventors that turned this bacterial defense system into a customizable gene editing system.

...

Caribou Biosciences is applying CRISPR-Cas technology to therapeutics, agriculture, biological research and industrial biotech. Caribou co-founded Intellia Therapeutics in 2014 to use CRISPR-Cas9 to develop cures to diseases like blood disorders and cancer. Caribou is also working on developing medicine for pets and agricultural livestock. It is working on antimicrobial therapies and the large-scale production of biological therapeutics. In a TechCrunch interview Haurwitz said that Caribou Biosciences has no plans to edit human embryos.

...

When CRISPR induces double stranded DNA breaks the cellular repair process causes some of the DNA sequence to be lost, which can disrupt gene function. While targeted disruption of genes is useful for some applications, the ability to change the DNA sequence to that of an introduced DNA template has broadened the applications of this technology. It is also possible to use CRISPR-Cas to make certain DNA changes without cutting. A modified CRISPR system uses a form of Cas9 with its cutting function inactivated, combined with other proteins to turn up or down gene expression levels without changing the DNA sequence.

...

There is a patent dispute between Doudna’s research team and the Broad Institute (MIT and Harvard) over the invention of CRISPR-Cas9 technology for use in human cells. The US patent granted to the Broad Institute is under appeal. The European patent office has revoked this first patent obtained by the Broad Institute citing lack of novelty. The European patent office has granted patents to the University of California and University of Vienna. One for using the CRISPR-Cas9 system across prokaryotic and eukaryotic systems and another for a modified form of CRISPR-Cas9 to regulate gene expression. Numerous patents have been assigned to Caribou Biosciences for CRISPR-Cas9 adaptations and other molecular biology materials.

...

Caribou Biosciences co-founded Intellia Therapeutics to use the Caribou CRISPR-Cas9 platform to develop therapeutics. Intellia Therapeutics is working with Regeneron to develop a gene knockout strategy for Transthyretin Amyloidosis (ATTR). CRISPR-Cas9 technology to knock out Hepatitis B Virus is being tested in animal models. Intellia is also developing the technology for gene editing in Alpha-1 Antitrypsin Deficiency (AATD) and Primary Hyperoxaluria (PH-1). Novartis is collaborating with Intellia to edit hemopoietic stem cells ex vivo at the BCL11A gene to treat Sickle Cell Disease. The two companies are also collaborating on Chimeric Antigen Receptor T Cell (CAR-T) strategies which modify the immune system so it better targets cancer.

Caribou Biosciences is developing cancer treatments in-house that target microbes that live on humans and other anti-microbial therapies.

...

Caribou Biosciences is collaborating with animal genetics company Genus (Basingstoke, UK) to improve the welfare of food producing animals. They are developing Porcine Reproductive and Respiratory Syndrome virus (PRRSv) resistant pigs. CRISPR-Cas9 technology was used to edit the CD163 gene in pigs, which makes the PRRSv unable to infect them.

...

DuPont collaborated with Caribou Biosciences to create drought and disease resistant waxy corn with CRISPR gene editing.

...

The Caribou technology platform is used to investigate the role of gene mutations in disease and find druggable targets. Manipulating gene function with CRISPR-Cas9 technology is also used to understand the normal function of genes.

...

The production of chemicals and enzymes for research and therapeutics requires cell factories for fermentation. Caribou Biosciences aims to improve microbial production strains for the production of therapeutic products. They are also using their technology to enable the bio-based production of materials never produced by microbes before, like fragrances, flavors, industrial cleaning products and products used in transportation.

Funding

Caribou raised a total disclosed funding of $74.6m from Anterra Capital, F-Prime Capital Partners, Heritage Group, Novartis, Genoa Ventures, and Jenny Rooke.

...

Funding

Series A

On April 2, 2015 Caribou Biosciences completed their series A funding round with $11 million in funding from Fidelity Biosciences, Novartis, Mission Bay Capital, 5 Prime Ventures, and an undisclosed strategic partner.

Series B

On May 16, 2016 Caribou Biosciences completed their series B funding round with $30 million in funding from Anterra Capital, Heritage Group, Maverick Capital Ventures, Pontifax AgTech, F-Prime Capital Partners, Novartis, Mission Bay Capital, and 5 Prime Ventures.

Documentaries, videos and podcasts

Title
Date
Link

Caribou Biosciences

October 18, 2018

Clipping out cancer with Caribou Biosciences | Disrupt NY 2017

May 16, 2017

Hacking the Genome / WHAT'S NEXT?

October 6, 2016

Panel: Next Generation Cell and Gene Therapy in Oncology

October 18, 2018

Infobox

Categories

Related Topics

Edits on 13 March, 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 13 March, 2019 8:22 pm
Edits made to:
Article (+25/-25 characters)

Article

Caribou Biosciences co-founded Intellia Therapeutics to use the Caribou CRISPR-Cas9 platform to develop therapeutics. Intellia Therapeutics is working with Regeneron to develop a gene knockout strategy for Transthyretin Amyloidosis (ATTR). CRISPR-Cas9 technology to knock out Hepatitis B Virus is being tested in animal models. Intellia is also developing the technology for gene editing in Alpha-1 Antitrypsin Deficiency (AATD) and Primary Hyperoxaluria (PH-1). Novartis is collaborating with Intellia to edit hemopoietic stem cells ex vivo at the BCL11A gene to treat Sickle Cell Disease. The two companies are also collaborating on Chimeric Antigen ReceptorChimeric Antigen Receptor T Cell (CAR-T) strategies which modify the immune system so it better targets cancer.

Edits on 7 March, 2019
Sameeha Sulaiman
Sameeha Sulaiman edited on 7 March, 2019 12:41 pm
Edits made to:
Infobox (+2 properties)
Edits on 6 February, 2019
Meredith Hanel
Meredith Hanel edited on 6 February, 2019 2:45 am
Edits made to:
Categories (+2 topics)
Edits on 21 January, 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 January, 2019 10:16 pm
Edits made to:
Infobox (+3/-3 properties)
Edits on 10 January, 2019
Golden AI
Golden AI edited on 10 January, 2019 12:22 pm
Edits made to:
Infobox (+1 properties)

Infobox

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.